HRP20171992T1 - Protutijela protiv cgrp - Google Patents
Protutijela protiv cgrp Download PDFInfo
- Publication number
- HRP20171992T1 HRP20171992T1 HRP20171992TT HRP20171992T HRP20171992T1 HR P20171992 T1 HRP20171992 T1 HR P20171992T1 HR P20171992T T HRP20171992T T HR P20171992TT HR P20171992 T HRP20171992 T HR P20171992T HR P20171992 T1 HRP20171992 T1 HR P20171992T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- amino acid
- antibody against
- human engineered
- engineered antibody
- Prior art date
Links
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 claims 8
- 102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57527—Calcitonin gene related peptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57545—Neuropeptide Y
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (8)
1. Ljudsko konstruirano protutijelo protiv CGRP, naznačeno time što sadrži varijabilno područje lakog lanca (LCVR) i varijabilno područje teškog lanca (HCVR), gdje navedeni LCVR sadrži aminokiselinske sljedove LCDR1, LCDR2, LCDR3, a HCVR sadrži aminokiselinske sljedove HCDR1, HCDR2, HCDR3, gdje je LCDR1 RASKDISKYLN (SEQ ID NO: 6), LCDR2 je YTSGYHS (SEQ ID NO: 7), LCDR3 je QQGDALPPT (SEQ ID NO: 5), HCDR1 je GYTFGNYWMQ (SEQ ID NO: 12), HCDR2 je AIYEGTGKTVYIQKFAD (SEQ ID NO: 16), a HCDR3 je LSDYVSGFGY (SEQ ID NO: 39).
2. Ljudsko konstruirano protutijelo protiv CGRP u skladu s patentnim zahtjevom 1, naznačeno time što je aminokiselinski slijed navedenog LCVR SEQ ID NO: 19, a aminokiselinski slijed navedenog HCVR je SEQ ID NO: 24.
3. Ljudsko konstruirano protutijelo protiv CGRP u skladu s patentnim zahtjevom 2, naznačeno time što navedeno protutijelo sadrži laki lanac i teški lanac, gdje je aminokiselinski slijed lakog lanca SEQ ID NO: 29, a aminokiselinski slijed teškog lanca je SEQ ID NO: 34.
4. Ljudsko konstruirano protutijelo protiv CGRP u skladu s patentnim zahtjevom 3, naznačeno time što navedeno protutijelo sadrži dva laka lanca i dva teška lanca, gdje je svaki aminokiselinski slijed lakog lanca SEQ ID NO: 29, a svaki aminokiselinski slijed teškog lanca je SEQ ID NO: 34.
5. Farmaceutski pripravak, naznačen time što sadrži ljudsko konstruirano protutijelo protiv CGRP u skladu s bilo kojim od patentnih zahtjeva 1-4, kao i farmaceutski prihvatljiv nosač, razrjeđivač ili pomoćnu tvar.
6. Ljudsko konstruirano protutijelo protiv CGRP u skladu s bilo kojim od patentnih zahtjeva 1-4, naznačeno time što je namijenjeno upotrebi u terapiji.
7. Ljudsko konstruirano protutijelo protiv CGRP u skladu s bilo kojim od patentnih zahtjeva 1-4, naznačeno time što je namijenjeno upotrebi u liječenju migrena.
8. Antigenski vežući fragment, naznačen time što je antigenski vežući fragment ljudskog konstruiranog protutijela protiv CGRP u skladu s bilo kojim od patentnih zahtjeva 1-4 ili 6-7.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35332310P | 2010-06-10 | 2010-06-10 | |
| EP11792989.3A EP2579894B1 (en) | 2010-06-10 | 2011-06-07 | Cgrp antibodies |
| PCT/US2011/039381 WO2011156324A1 (en) | 2010-06-10 | 2011-06-07 | Cgrp antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171992T1 true HRP20171992T1 (hr) | 2018-02-09 |
Family
ID=45096388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171992TT HRP20171992T1 (hr) | 2010-06-10 | 2017-12-21 | Protutijela protiv cgrp |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US9073991B2 (hr) |
| EP (2) | EP2579894B1 (hr) |
| JP (2) | JP6021806B2 (hr) |
| KR (1) | KR101489566B1 (hr) |
| CN (2) | CN102946905B (hr) |
| AR (1) | AR081434A1 (hr) |
| AU (1) | AU2011265050B2 (hr) |
| BR (1) | BR112012031501B1 (hr) |
| CA (1) | CA2802102C (hr) |
| CY (2) | CY1119789T1 (hr) |
| DK (1) | DK2579894T3 (hr) |
| EA (1) | EA022931B1 (hr) |
| ES (2) | ES2930321T3 (hr) |
| HK (1) | HK1203211A1 (hr) |
| HR (1) | HRP20171992T1 (hr) |
| HU (2) | HUE038135T2 (hr) |
| IL (2) | IL222885B (hr) |
| JO (1) | JO3330B1 (hr) |
| LT (2) | LT2579894T (hr) |
| LU (1) | LUC00112I2 (hr) |
| ME (1) | ME02862B (hr) |
| MX (2) | MX363209B (hr) |
| NL (1) | NL300979I2 (hr) |
| NO (2) | NO2579894T3 (hr) |
| NZ (1) | NZ603607A (hr) |
| PL (1) | PL2579894T3 (hr) |
| PT (1) | PT2579894T (hr) |
| RS (1) | RS56638B1 (hr) |
| SG (1) | SG185648A1 (hr) |
| SI (1) | SI2579894T1 (hr) |
| TW (1) | TWI423818B (hr) |
| UA (1) | UA109658C2 (hr) |
| WO (1) | WO2011156324A1 (hr) |
| ZA (1) | ZA201208996B (hr) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1957106T4 (da) | 2005-11-14 | 2019-10-28 | Teva Pharmaceuticals Int Gmbh | Antagonist-antistoffer, der er rettet mod calcitonin-gen-relateret peptid og fremgangsmåder til anvendelse af disse |
| ES2689322T3 (es) | 2008-03-04 | 2018-11-13 | Teva Pharmaceuticals International Gmbh | Métodos para tratar el dolor crónico |
| US8623366B2 (en) | 2009-08-28 | 2014-01-07 | Labrys Biologics, Inc. | Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide |
| JO3330B1 (ar) * | 2010-06-10 | 2019-03-13 | Lilly Co Eli | الأجسام المضادة cgrp |
| MX356269B (es) | 2011-05-20 | 2018-05-21 | Alderbio Holdings Llc | Uso de anticuerpos anti-cgrp y fragmentos de anticuerpo para prevenir o inhibir la fotofobia o aversion a la luz en sujetos en necesidad de los mismos, especialmente pacientes con migraña. |
| CN103957935B (zh) | 2011-05-20 | 2018-04-03 | 奥尔德生物控股有限责任公司 | 抗cgrp或抗cgrp‑r抗体或抗体片段用于治疗或预防慢性和急性形式的腹泻的用途 |
| WO2012162243A2 (en) | 2011-05-20 | 2012-11-29 | Alderbio Holdings Llc | Anti-cgrp compositions and use thereof |
| PT2888283T (pt) | 2012-08-24 | 2018-11-16 | Univ California | Anticorpos e vacinas para serem utilizados no tratamento de cancros que expressam ror1 e inibição de metástases |
| US10556945B2 (en) * | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| KR20220130822A (ko) | 2014-03-21 | 2022-09-27 | 테바 파마슈티컬스 인터내셔널 게엠베하 | 칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법 |
| JP6581656B2 (ja) | 2014-10-24 | 2019-09-25 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | グルカゴンおよびｇｌｐ−１受容体のコアゴニスト |
| TWI595006B (zh) * | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| JOP20200116A1 (ar) | 2015-04-24 | 2017-06-16 | Amgen Inc | طرق لعلاج أو الوقاية من الصداع النصفي |
| AR104847A1 (es) * | 2015-06-17 | 2017-08-16 | Lilly Co Eli | Formulación de anticuerpo anti-cgrp |
| WO2017074428A1 (en) * | 2015-10-30 | 2017-05-04 | Eli Lilly And Company | Anti-cgrp/anti-il-23 bispecific antibodies and uses thereof |
| CN105483091A (zh) * | 2015-12-29 | 2016-04-13 | 天津三箭生物技术股份有限公司 | 小鼠抗人Calcitonin单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株 |
| CA3007018A1 (en) * | 2016-01-28 | 2017-08-03 | Eli Lilly And Company | Cgrp antibodies and uses thereof |
| CA3013443C (en) | 2016-02-01 | 2021-06-15 | Eli Lilly And Company | Parathyroid hormone - anti-rankl antibody fusion compounds |
| KR20230047507A (ko) | 2016-06-27 | 2023-04-07 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 암 치료 조합 |
| JP2019529463A (ja) | 2016-09-23 | 2019-10-17 | テバ・ファーマシューティカルズ・インターナショナル・ゲー・エム・ベー・ハー | 群発頭痛の治療方法 |
| EP3515937A1 (en) | 2016-09-23 | 2019-07-31 | Teva Pharmaceuticals International GmbH | Treating refractory migraine |
| KR20190133174A (ko) * | 2017-03-02 | 2019-12-02 | 베쓰 이스라엘 디코니스 메디칼 센터 인크 | 칼시토닌 유전자 관련 펩티드에 대해 지시되는 항체에 반응하는 두통 환자를 선택하는 방법 |
| TW201902926A (zh) | 2017-05-03 | 2019-01-16 | 美商美國禮來大藥廠 | 抗cgrp／抗il-23雙特異性抗體及其用途 |
| KR102618831B1 (ko) | 2017-06-21 | 2023-12-28 | 세파론 엘엘씨 | 양이온 교환 크로마토그래피 세척 완충액 |
| TWI754772B (zh) | 2017-09-06 | 2022-02-11 | 美商美國禮來大藥廠 | 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法 |
| US10738110B2 (en) | 2018-01-12 | 2020-08-11 | Amgen Inc. | PAC1 antibodies and uses thereof |
| WO2019231800A1 (en) | 2018-05-31 | 2019-12-05 | Eli Lilly And Company | Anti-cgrp antibodies for treating menstrual-related migraines |
| MA53436A (fr) | 2018-08-22 | 2021-12-01 | Lilly Co Eli | Anticorps anti-cgrp pour patients résistants au traitement |
| CR20210373A (es) | 2019-01-08 | 2021-08-19 | H Lundbeck As | Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp |
| EP3744400A1 (en) * | 2019-05-28 | 2020-12-02 | Etablissement Français du Sang | Car-t cells targeting il-1rap and their use in acute myeloid leukemia (aml) |
| CN114127110B (zh) * | 2019-05-30 | 2022-07-01 | 山东博安生物技术股份有限公司 | 抗cgrp抗体及其应用 |
| CN114555792A (zh) | 2019-10-15 | 2022-05-27 | 伊莱利利公司 | 重组改造的、脂肪酶/酯酶缺陷型哺乳动物细胞系 |
| MX2023010115A (es) | 2021-03-02 | 2023-11-09 | Cgrp Diagnostics Gmbh | Tratamiento y/o reducción de la aparición de la migraña. |
| WO2023161526A1 (en) | 2022-02-28 | 2023-08-31 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN |
| WO2024032750A1 (zh) * | 2022-08-11 | 2024-02-15 | 上海君实生物医药科技股份有限公司 | 抗cgrp抗体及用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ES2134212T3 (es) * | 1991-04-25 | 1999-10-01 | Chugai Pharmaceutical Co Ltd | Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano. |
| ATE255131T1 (de) * | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| WO2005035753A1 (ja) | 2003-10-10 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | 機能蛋白質を代替する二重特異性抗体 |
| CA2603940A1 (en) * | 2005-04-08 | 2006-10-19 | Nancy Ulbrandt | Antibodies against mammalian metapneumovirus |
| DK1957106T4 (da) * | 2005-11-14 | 2019-10-28 | Teva Pharmaceuticals Int Gmbh | Antagonist-antistoffer, der er rettet mod calcitonin-gen-relateret peptid og fremgangsmåder til anvendelse af disse |
| WO2007076336A1 (en) * | 2005-12-22 | 2007-07-05 | Eli Lilly And Company | Treatment of migraine with anti-cgrp antibodies |
| RU2467765C2 (ru) | 2008-03-04 | 2012-11-27 | Пфайзер Лимитед | Способы лечения воспалительной боли |
| ES2689322T3 (es) * | 2008-03-04 | 2018-11-13 | Teva Pharmaceuticals International Gmbh | Métodos para tratar el dolor crónico |
| JO3330B1 (ar) * | 2010-06-10 | 2019-03-13 | Lilly Co Eli | الأجسام المضادة cgrp |
-
2011
- 2011-05-31 JO JOP/2011/0177A patent/JO3330B1/ar active
- 2011-05-31 AR ARP110101867A patent/AR081434A1/es active IP Right Grant
- 2011-06-03 TW TW100119683A patent/TWI423818B/zh active
- 2011-06-07 DK DK11792989.3T patent/DK2579894T3/en active
- 2011-06-07 EP EP11792989.3A patent/EP2579894B1/en active Active
- 2011-06-07 NO NO11792989A patent/NO2579894T3/no unknown
- 2011-06-07 PT PT117929893T patent/PT2579894T/pt unknown
- 2011-06-07 BR BR112012031501-3A patent/BR112012031501B1/pt active IP Right Grant
- 2011-06-07 ES ES17201603T patent/ES2930321T3/es active Active
- 2011-06-07 ME MEP-2017-280A patent/ME02862B/me unknown
- 2011-06-07 MX MX2016005150A patent/MX363209B/es unknown
- 2011-06-07 US US13/154,538 patent/US9073991B2/en active Active
- 2011-06-07 CA CA2802102A patent/CA2802102C/en active Active
- 2011-06-07 RS RS20171265A patent/RS56638B1/sr unknown
- 2011-06-07 LT LTEP11792989.3T patent/LT2579894T/lt unknown
- 2011-06-07 SG SG2012084885A patent/SG185648A1/en unknown
- 2011-06-07 AU AU2011265050A patent/AU2011265050B2/en active Active
- 2011-06-07 MX MX2012014480A patent/MX340999B/es active IP Right Grant
- 2011-06-07 EP EP17201603.2A patent/EP3318272B1/en active Active
- 2011-06-07 SI SI201131359T patent/SI2579894T1/en unknown
- 2011-06-07 WO PCT/US2011/039381 patent/WO2011156324A1/en active Application Filing
- 2011-06-07 KR KR1020127032068A patent/KR101489566B1/ko active IP Right Grant
- 2011-06-07 PL PL11792989T patent/PL2579894T3/pl unknown
- 2011-06-07 HU HUE11792989A patent/HUE038135T2/hu unknown
- 2011-06-07 CN CN201180028611.1A patent/CN102946905B/zh active Active
- 2011-06-07 JP JP2013514281A patent/JP6021806B2/ja active Active
- 2011-06-07 NZ NZ603607A patent/NZ603607A/en unknown
- 2011-06-07 EA EA201270769A patent/EA022931B1/ru not_active IP Right Cessation
- 2011-06-07 ES ES11792989.3T patent/ES2656000T3/es active Active
- 2011-06-07 CN CN201410474677.9A patent/CN104292332B/zh active Active
- 2011-07-06 UA UAA201212663A patent/UA109658C2/ru unknown
-
2012
- 2012-11-05 IL IL222885A patent/IL222885B/en active Protection Beyond IP Right Term
- 2012-11-28 ZA ZA2012/08996A patent/ZA201208996B/en unknown
-
2015
- 2015-04-20 HK HK15103793.6A patent/HK1203211A1/xx unknown
- 2015-06-04 US US14/730,270 patent/US9505838B2/en active Active
- 2015-11-02 IL IL242409A patent/IL242409B/en active IP Right Grant
-
2016
- 2016-06-28 JP JP2016127666A patent/JP6466883B2/ja active Active
- 2016-11-02 US US15/341,166 patent/US20170073403A1/en not_active Abandoned
-
2017
- 2017-12-21 HR HRP20171992TT patent/HRP20171992T1/hr unknown
-
2018
- 2018-01-18 CY CY20181100064T patent/CY1119789T1/el unknown
-
2019
- 2019-04-02 CY CY2019017C patent/CY2019017I1/el unknown
- 2019-04-02 HU HUS1900020C patent/HUS1900020I1/hu unknown
- 2019-04-05 NO NO2019017C patent/NO2019017I1/no unknown
- 2019-04-09 LU LU00112C patent/LUC00112I2/fr unknown
- 2019-04-11 NL NL300979C patent/NL300979I2/nl unknown
- 2019-04-12 LT LTPA2019011C patent/LTC2579894I2/lt unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171992T1 (hr) | Protutijela protiv cgrp | |
| HRP20160151T1 (hr) | PROTUTIJELA PROTIV N3pGlu-AMILOIDNOG BETA PEPTIDA I NJIHOVA UPOTREBA | |
| NZ610294A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
| NZ628943A (en) | Human antibodies to clostridium difficile toxins | |
| HRP20211343T1 (hr) | Protutijela protiv dkk-1 | |
| NZ600768A (en) | Human antibodies to human angiopoietin-like protein 4 | |
| PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| JP2013542194A5 (hr) | ||
| MX2019007848A (es) | Anticuerpos anti-pd-1 y usos de los mismos. | |
| HRP20151019T1 (hr) | PROTUTIJELA PROTIV c-MET | |
| AR110203A1 (es) | Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1 | |
| HRP20161587T1 (hr) | Protutijela protiv bmp-6 | |
| NZ729913A (en) | St2l antagonists and methods of use | |
| RS53661B1 (en) | HIGH AFINITY ANTIBODY ANTIBODIES TO THE HUMAN NERVOUS FACTOR OF GROWTH | |
| NZ600512A (en) | Neutralizing prolactin receptor antibodies and their therapeutic use | |
| NZ610734A (en) | Human antibodies to the glucagon receptor | |
| CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
| NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
| NZ598391A (en) | Anti-hepcidin antibodies and uses thereof | |
| PE20090161A1 (es) | Anticuerpos monoclonales anti cxcl13 | |
| RU2015110981A (ru) | Комбинации и их применение | |
| JP2015530399A5 (hr) | ||
| NZ592436A (en) | Treatment with anti-alpha2 integrin antibodies | |
| AR098663A1 (es) | Anticuerpos multifuncionales que se unen a egfr y met | |
| HRP20211059T1 (hr) | Antitijela za il-17c |